Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Free Cash Flow history runs 14 years deep, the most recent figure standing at -$119.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 29.05% year-over-year to -$119.7 million in Q1 2026; TTM through Mar 2026 was -$303.8 million, a 8.37% decrease from a year earlier, with the FY2025 full-year figure at -$276.9 million, down 18.92% from the prior year.
• Free Cash Flow eased to -$119.7 million in Q1 2026 per VRDN's latest filing, from -$24.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$17.9 million in Q2 2022 and bottomed at -$119.7 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$45.5 million (2023), against an average of -$53.5 million.
• Across the five-year window, Free Cash Flow slumped 192.58% in 2023 and surged 67.33% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$33.9 million in 2022, then slipped by 12.38% to -$38.0 million in 2023, then plunged by 93.04% to -$73.4 million in 2024, then jumped by 67.33% to -$24.0 million in 2025, then plunged by 398.78% to -$119.7 million in 2026.
• Per Business Quant, the three latest VRDN Free Cash Flow figures stand at -$119.7 million (Q1 2026), -$24.0 million (Q4 2025), and -$84.7 million (Q3 2025).